<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02504580</url>
  </required_header>
  <id_info>
    <org_study_id>HTX-011-C2015-202</org_study_id>
    <nct_id>NCT02504580</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy</brief_title>
  <official_title>A Phase 2, Randomized, Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heron Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heron Therapeutics</source>
  <brief_summary>
    <textblock>
      A Phase 2, Randomized, Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and&#xD;
      Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical&#xD;
      Application Following Unilateral Open Inguinal Herniorrhaphy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy endpoint (Summed pain intensity (SPI)</measure>
    <time_frame>24 Hours</time_frame>
  </primary_outcome>
  <number_of_arms>23</number_of_arms>
  <enrollment type="Actual">463</enrollment>
  <condition>Analgesia in Patients With Inguinal Herniorrhaphy</condition>
  <arm_group>
    <arm_group_label>Part A Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg of HTX-011 by injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg of HTX-011 by injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg of HTX-011 by instillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Cohort D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg of HTX-011 by instillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Cohort E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg HTX-011 injection and 200 mg instillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Cohort F</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution by injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg HTX-011A by injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg HTX-011A by injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg HTX-011B by injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Cohort D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg HTX-011B by injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Cohort E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution by injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg HTX-002 by infiltration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Cohort F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg HTX-002 by infiltration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg HTX-011B by instillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Cohort G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg HTX-011B by instillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C Cohort C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Solution by instillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C Cohort D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.25% bupivacaine hydrochloride injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg HTX-011B via a combination of injection and instillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part E Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTX-009 by injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part E Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTX-009 by instillation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part F Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg of HTX-011B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part F Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 mg of 0.25% Marcaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part F Cohort C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10.26 mL of normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTX-011</intervention_name>
    <arm_group_label>Part A Cohort A</arm_group_label>
    <arm_group_label>Part A Cohort B</arm_group_label>
    <arm_group_label>Part A Cohort C</arm_group_label>
    <arm_group_label>Part A Cohort D</arm_group_label>
    <arm_group_label>Part A Cohort E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Part A Cohort F</arm_group_label>
    <arm_group_label>Part B Cohort E</arm_group_label>
    <arm_group_label>Part C Cohort C</arm_group_label>
    <arm_group_label>Part F Cohort C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTX-002</intervention_name>
    <arm_group_label>Part B Cohort F</arm_group_label>
    <arm_group_label>Part C Cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Hydrochloride Injection</intervention_name>
    <arm_group_label>Part C Cohort D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTX-011A</intervention_name>
    <arm_group_label>Part B Cohort A</arm_group_label>
    <arm_group_label>Part B Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTX-011B</intervention_name>
    <arm_group_label>Part B Cohort C</arm_group_label>
    <arm_group_label>Part B Cohort D</arm_group_label>
    <arm_group_label>Part B Cohort G</arm_group_label>
    <arm_group_label>Part C Cohort B</arm_group_label>
    <arm_group_label>Part D Cohort A</arm_group_label>
    <arm_group_label>Part F Cohort A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTX-009</intervention_name>
    <arm_group_label>Part E Cohort A</arm_group_label>
    <arm_group_label>Part E Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marcaine</intervention_name>
    <arm_group_label>Part F Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be male or female 18 years of age or older.&#xD;
&#xD;
          2. Female subjects are eligible only if all of the following apply:&#xD;
&#xD;
             Not pregnant (female subject of child bearing potential must have a negative serum&#xD;
             pregnancy test at screening and negative urine pregnancy test before surgery)&#xD;
&#xD;
               -  Not lactating&#xD;
&#xD;
               -  Not planning to become pregnant during the study&#xD;
&#xD;
               -  Be surgically sterile; or at least two years post-menopausal; or have a&#xD;
                  monogamous partner who is surgically sterile; or is practicing double-barrier&#xD;
                  contraception; or practicing abstinence (must agree to use double-barrier&#xD;
                  contraception in the event of sexual activity); or using an insertable,&#xD;
                  injectable, transdermal, or combination oral contraceptive approved by the FDA&#xD;
                  for greater than 2 months prior to screening visits and commits to the use of an&#xD;
                  acceptable form of birth control for the duration of the study and for 30 days&#xD;
                  from completion of the study&#xD;
&#xD;
             Male:&#xD;
&#xD;
             o Must be surgically sterile (biologically or surgically) or commit to the use of a&#xD;
             reliable method of birth control for the duration of the study until at least 1 week&#xD;
             after the administration of study medication.&#xD;
&#xD;
          3. Plan to undergo a unilateral inguinal herniorrhaphy&#xD;
&#xD;
          4. Have the ability and be willing to comply with the study procedures&#xD;
&#xD;
          5. Must be able to understand study procedures and give informed consent for the conduct&#xD;
             for all study procedures, using an IRB approved consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unwilling to sign informed consent or not willing or able to complete all study&#xD;
             procedures&#xD;
&#xD;
          2. Have a contraindication or be allergic to any medication to be used during the trial&#xD;
             period&#xD;
&#xD;
          3. Have clinically significant cardiac abnormalities, that in the opinion of the&#xD;
             investigator would pose a health risk to the subject should they participate in the&#xD;
             trial&#xD;
&#xD;
          4. Have American Society of Anesthesiologists (ASA) Physical Status classification system&#xD;
             category 4 or greater (Appendix E)&#xD;
&#xD;
          5. Have clinically significant renal or hepatic abnormalities (defined as an AST or ALT &gt;&#xD;
             3x ULN, creatinine &gt; 2x ULN)&#xD;
&#xD;
          6. Have another painful condition that may confound pain assessments&#xD;
&#xD;
          7. Have another surgery planned within 30 days of procedure, or presents with bilateral&#xD;
             or recurrent inguinal hernia, other hernia presentations, or hernias with large&#xD;
             scrotal component that would be difficult to reduce surgically&#xD;
&#xD;
          8. Have a known or suspected history of alcohol or drug abuse, or a positive drug screen&#xD;
&#xD;
          9. Currently taking analgesics for a chronically painful condition, or has taken long&#xD;
             acting opioids within 3 days of surgery, or taken any opioids within 24 hours of&#xD;
             surgery&#xD;
&#xD;
         10. Subjects with documented sleep apnea or are on home continuous positive airway&#xD;
             pressure (CPAP)&#xD;
&#xD;
         11. Female subjects who are pregnant (positive pregnancy test at screening or on the day&#xD;
             of surgery)&#xD;
&#xD;
         12. Subjects who are receiving oxygen therapy at the time of screening&#xD;
&#xD;
         13. Have participated in a clinical trial within 30 days of planned surgery&#xD;
&#xD;
         14. Have a body mass index (BMI) &gt; 39 kg/m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>July 16, 2015</study_first_submitted>
  <study_first_submitted_qc>July 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2015</study_first_posted>
  <disposition_first_submitted>June 8, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>June 8, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 12, 2018</disposition_first_posted>
  <last_update_submitted>June 8, 2018</last_update_submitted>
  <last_update_submitted_qc>June 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia, Inguinal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 14, 2021</submitted>
    <returned>July 2, 2021</returned>
    <submitted>October 15, 2021</submitted>
    <returned>November 12, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

